The Scientist Turned VC Funding the Cure for Aging with Omri Amirav-Drory скачать в хорошем качестве

The Scientist Turned VC Funding the Cure for Aging with Omri Amirav-Drory

What if aging isn’t inevitable — but a solvable problem? And what if the biggest opportunity in healthcare isn’t treating disease, but preventing it entirely? In this episode of Ventures from the Valley, I sit down with Omri Amirav-Drory, General Partner at NFX, to explore one of the most ambitious frontiers in venture capital: longevity, biotech, and the intersection of biology and technology. Omri leads pre-seed and seed investments at NFX and focuses on what he believes is the ultimate mission — ending involuntary death. We talk openly about why aging is the root cause behind most diseases, how AI is transforming biotech, and why longevity represents a $38 trillion per year opportunity in additional healthy life. This is a deep, honest conversation about conviction, risk, optimism, and why the future of healthcare looks nothing like today’s system. ⸻ In this episode, we discuss: • Why aging is the root cause of 9 out of 10 deadly diseases • The real difference between lifespan and healthspan • Why longevity could unlock $38T per year in economic value • How NFX evaluates early-stage biotech and tech-bio startups • The power-law logic behind seed investing • Why most VCs miss the biggest opportunities by being pessimistic • AI’s three major waves in biotech and drug discovery • Why GLP-1 drugs changed healthcare economics forever • Precision medicine, biomarkers, and the limits of simulation • Whether humans alive today could realistically live to 160 • Replacement biology, regeneration, and the ethics of enhancement ❓ Do you believe aging will be cured in our lifetime — or is it science fiction? ⸻ Timestamps 00:00 – Can Humans Live to 160? 01:36 – Omri’s Background 02:56 – What Is Tech-Bio Investing? 04:20 – How NFX Is Structured 05:52 – How Investment Decisions Are Made 07:31 – Why Power-Law Thinking Drives Early-Stage VC 09:22 – Offense vs Defense 11:05 – Using AI to Manage Massive Deal Flow 12:20 – Signal vs Noise in Startup Selection 14:12 – Why Paid Introductions Are a Red Flag 16:01 – Leading vs Following in Seed Rounds 18:05 – Board Seats and Founder Accountability 19:48 – The Power-Law Rule 22:03 – Market Cycles and Seed Investing 23:21 – Optimism vs Pessimism in Venture Capital 25:10 – The Emotional Reality of Investing 26:54 – Longevity as an Investment Thesis 27:54 – Why Aging Is the Real Disease 29:03 – Lifespan vs Healthspan Explained 30:15 – Why Staying Young Solves Economic Problems 32:02 – GLP-1 Drugs and Root-Cause Medicine 33:19 – The “Race to 160” Explained 35:01 – Plan A, B, C, and D for Aging 36:40 – Replacement Biology and Regeneration 38:01 – Longevity Companies NFX Invests In 39:31 – AI, Biology, and the Future of Medicine 45:14 – Why Biotech AI Is Undervalued 48:01 – The Three Waves of AI in Biotech 52:13 – Precision Medicine and Biomarkers 56:02 – Genetic Selection and Human Enhancement 58:11 – Will Longevity Create Inequality? 59:45 – Final Thoughts on the Future of Life ___________________________________________________________________________ Watch Next:    • Why Venture Capital Outperforms Other Inve...      • How China Actually Builds Tech Giants with...      • From Knives to SaaS: Building, Scaling, an...   Watch this video:    • The Scientist Turned VC Funding the Cure f...   ___________________________________________________________________________ R136 Ventures - a Silicon Valley-based multi-stage VC firm with a focus on scaling mid and late-stage B2B and fintech startups. Our mission is to propel creative entrepreneurs to a faster growth trajectory. We help founders scale their mid-to-late stage startups, bringing with us a distinctive fusion of expertise and past experiences that are key in unlocking their true potential. With many of our team having previously held CEO, CTO and other c-level positions, we understand the challenges and opportunities of both startups and major corporations. Our contribution doesn't just stop at vision and strategy; we actively shape your execution and help in talent acquisition. With a legacy of managing assets exceeding $400 million and having financially backed more than 30 innovative companies, our record speaks for itself. 🌐 Learn more: https://www.r136.vc/ #venturecapital #startups #R136 #Longevity